Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas.
D DanielsDavid GoezD LastChen HoffmannD NassA TalianskiG TsarfatyS SalomonA A KannerDeborah T BlumenthalFelix BoksteinS HarnofD YekutieliS ZamirZvi R CohenL ZachYael MardorPublished in: AJNR. American journal of neuroradiology (2016)
The benefit of contrast-enhanced MR imaging for assessing and predicting the response to bevacizumab was demonstrated. The increased sensitivity of the treatment-response-assessment maps reflects their potential contribution to the management of bevacizumab-treated patients with recurrent high-grade glioma.